Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hemophilia Carriers Face Elevated Risk of Joint Comorbidities

Key clinical point: Hemophilia carriers have a higher risk of joint-related comorbidities than the general population.

Major finding: Hemophilia carriers with reduced factor activity have a 2.3-fold higher risk of a joint diagnosis (95% CI, 1.1-4.5).

Study details: Analysis of registry data for 539 potential carriers of impaired factor VIII or IX gene.

Disclosures: All authors declared that they had no conflict of interest related to the study findings. Four of the authors reported financial ties to companies including Novo Nordisk, Shire, and Bayer.

Citation:

Osooli M et al. Haemophilia. 2019 Aug 14. doi: 10.1111/hae.13831.